Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06909474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Name: Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies — clinical trial record (NCT06909474)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2025-03-27

View on ClinicalTrials.gov ↗

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Acute Lymphoblastic Leukemia (ALL)

873 trials monitored

See 52 trials at risk

This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.

Trial Details

NCT Number	NCT06909474
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	T-ALL/Lymphoma
Enrollment	15 participants
Start Date	2025-03-27
Primary Completion	2027-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-03